AstraZeneca (AZN) and Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology. Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets. Alteogen will be responsible for clinical and commercial supply of ALT-B4 to AstraZeneca. AstraZeneca will make an upfront payment to Alteogen and additional payments upon achievement of specific development, regulatory and sales-related milestones. Additionally, Alteogen will receive royalties on the sales of the commercialised products.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca’s Promising Pipeline and Attractive Valuation Drive Buy Rating
- AstraZeneca to acquire EsoBiotec for $425M upfront
- Inovio reports ‘promising’ interim results from DMAbs trial
- Cellectis reports Q4 EPS (64c) vs (17c) last year
- AstraZeneca’s Promising Future: Buy Rating Backed by Robust Pipeline and Strong Sales Potential
Questions or Comments about the article? Write to editor@tipranks.com